After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...